Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 againstc-Myc-overexpressing human B-cell non-Hodgkin lymphomas,

Carla Guarnotta, Roberta Zappasodi, Claudia Piovan, Massimo Di Nicola, Alessandro M. Gianni, Alessandra Cavanè, Giusi Ruggiero, Monica Tortoreto, Elda Tagliabue, Nadia Zaffaroni, Michele Magni, Franco Zunino, Carlo M. Croce, Marilena V. Iorio

    Risultato della ricerca: Articlepeer review

    15 Citazioni (Scopus)

    Abstract

    Histone deacetylases (HDAC) extensively contribute to the c-Myc oncogenic program, pointing to their inhibition as an effective strategy against c-Myc-overexpressing cancers. We, thus, studied the therapeutic activity of the new-generation pan-HDAC inhibitor ITF2357 (Givinostat®) against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas (B-NHLs). ITF2357 anti-proliferative and pro-apoptotic effects were analyzed in B-NHL cell lines with c-Myc translocations (Namalwa, Raji and DOHH-2), stabilizing mutations (Raji) or post-transcriptional alterations (SU-DHL-4) in relationship to c-Myc modulation. ITF2357 significantly delayed the in vitro growth of all B-NHL cell lines by inducing G1 cell-cycle arrest, eventually followed by cell death. These events correlated with the extent of c-Myc protein, but not mRNA, downregulation, indicating the involvement of post-transcriptional mechanisms. Accordingly, c-Myc-targeting microRNAs let-7a and miR-26a were induced in all treated lymphomas and the cap-dependent translation machinery components 4E-BP1, eIF4E and eIF4G, as well as their upstream regulators, Akt and PIM kinases, were inhibited in function of the cell sensitivity to ITF2357, and, in turn, c-Myc downregulation. In vivo, ITF2357 significantly hampered the growth of Namalwa and Raji xenografts in immunodeficient mice. Noteworthy, its combination with suboptimal cyclophosphamide, achieved complete remissions in most animals and equaled or even exceeded the activity of optimal cyclophosphamide. Collectively, our findings provide the rationale for testing the clinical advantages of adding ITF2357 to current therapies for the still very ominous c-Myc-overexpressing lymphomas. They equally provide the proof-of-concept for its clinical evaluation in rational combination with the promising inhibitors of B-cell receptor and PI3K/Akt/mTOR axis currently in the process of development.
    Lingua originaleEnglish
    pagine (da-a)2034-2045
    Numero di pagine12
    RivistaInternational Journal of Cancer
    Volume135
    Stato di pubblicazionePublished - 2014

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Cancer Research

    Fingerprint Entra nei temi di ricerca di 'Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 againstc-Myc-overexpressing human B-cell non-Hodgkin lymphomas,'. Insieme formano una fingerprint unica.

    Cita questo